TVTX - Conference and earnings call announcements

Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria FILSPARI was generally well tolerated for up to five years of follow-up in the study Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerul

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS,

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is

New PDUFA target action date is April 13, 2026 Commercial launch preparations continue in anticipation of potential approval Travere Therapeutics, Inc., (NASDAQ:TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI. The FDA determined that the additional responses constituted a Major Amendment (MA) to

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT. A live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this p

New late-breaking data from DUPLEX Study show significantly more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan FILSPARI treatment associated with a clinically meaningful lower risk of kidney failure events over five years compared with irbesartan in DUPLEX-aligned RaDaR cohort Data support findings of PARASOL Project, reinforcing that reaching proteinuria below 0.7 g/g is associated with long-term kidney preservation Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® (sparsentan) were signific

Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee is no longer needed. The sNDA remains under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026. "FSGS is a leading cause of kidney failure, and for too long patients have been waiting for approved therapies for this rare and devastating disease," said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. "We are

PDUFA target action date of January 13, 2026 If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026, and has indicated that it is currently planning to hold an advisory committee meeting to discuss the application. "Today marks

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (F

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT. A live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that company management will present in the following upcoming investor conferences in December: 7th Annual Evercore HealthCONx ConferenceTuesday, December 3, 2024, at 10:00 a.m. ET Citi 2024 Global Healthcare ConferenceWednesday, December 4, 2024, at 2:30 p.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event. About Travere TherapeuticsAt Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that come

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that company management will present in the following upcoming investor conferences in November: Guggenheim Securities Healthcare Innovation ConferenceMonday, November 11, 2024, at 2:30 p.m. ET Jefferies London Healthcare ConferenceWednesday, November 20, 2024, at 8:30 a.m. GMT Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event. About Travere TherapeuticsAt Travere Therapeutics, we are in rare for life. We are a biopharmaceutical com

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know t

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN Ligand

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow Healthcare ConferenceTuesday, August 13, 2024, at 2:30 p.m. ET Canaccord Genuity 44th Annual Growth ConferenceWednesday, August 14, 2024, at 12:30 p.m. ET A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in ra

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we kn

Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation (NKF) Spring Clinical Meetings in Long Beach, California, May 14-18, 2024, and the European Renal Association (ERA) Congress in Stockholm, May 23-26, 2024. At NKF the Company will present analyses comparing the effect of FILSPARI (sparsentan) as seen in the Phase 3 PROTECT Study in slowing kidney function decline versus R

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities Health Care Conference Wednesday, May 15, 2024, at 8:00 a.m. PT Jefferies Global Healthcare ConferenceWednesday, June 5, 2024, at 3:00 p.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day

First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) to full approval. In February 2023, the FDA granted accelerated approval to FILSPARI as the first and only non-immunosuppressive treatment targeting glomerular injury in the kidney to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. The sNDA is based on 2-year confirmatory results from the Phase 3 PROTECT Study, the only head-to-head study

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming investor conferences in March: Cowen 44th Annual Health Care ConferenceMonday, March 4, 2024, at 9:10 a.m. ET Leerink Partners Global Biopharma ConferenceMonday, March 11, 2024, at 1:20 p.m. ET Barclays 26th Annual Global Healthcare ConferenceTuesday, March 12, 2024, at 2:05 p.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event. About Travere Therapeutics At Travere

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we kno

SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 p.m. PT. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgAN to full approval Following engagement with the FDA on the two-year results from the Phase 3 DUPLEX Study in FSGS, Company conducting additional analyses of FSGS data and plans to re-engage FDA in 2024 Company is implementing a strategic reorganization to further focus near-term resources on ongoing FILSPARI launch in IgAN and advancement of pegtibatinase in classical HCU, extending expected cash runway into 2028 SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:T

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure, suggesting long-term benefits in IgAN and FSGS In PROTECT, the only head-to-head study conducted to date in IgAN, FILSPARI® (sparsentan) showed one of the slowest rates of kidney function decline in IgAN trials, consistent treatment effects across baseline eGFR and proteinuria, and higher rates of complete remission compared to maximally tolerated dose of irbesartan through 110 weeks of treatment In DUPLEX, the largest interventional study in FSGS and only study against a maximally dosed act

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for presentation highlight Travere's leadership and commitment in the field of rare kidney disease SAN DIEGO, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 2-5, 2023. Presentations will highlight the long-term efficacy and tolerability data of FILSPARI® (sparsentan) in I

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) ("Travere") today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) versus irbesartan. FILSPARI demonstrated long-term kidney function preservation and achieved a clinically meaningful difference in estimated glomerular filtration rate (eGFR) total and chronic slope versus irbesartan, narrowly missing statistical significance in eGFR total slope while achieving statistical significance in eGFR chronic slope for purposes of regulatory review in the EU. FIL

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023, at 10:15 a.m. ET. A live webcast will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the n

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: William Blair 43rd Annual Growth Stock ConferenceTuesday, June 6, 2023, at 12:40 p.m. CT Jefferies Healthcare ConferenceWednesday, June 7, 2023, at 11:00 a.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every

SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease DaysTuesday, April 4, 2023, at 3:55 p.m. ET BofA Securities 2023 Health Care ConferenceWednesday, May 10, 2023, at 3:40 p.m. PT Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company tha

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. active control, irbesartan Ligand is entitled to receive a net $15.3 million milestone and net royalties of 9% on future sales Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN a

SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities Global Biopharma ConferenceWednesday, February 15, 2023, at 3:00 p.m. ET Barclays Global Healthcare ConferenceWednesday, March 15, 2023, at 11:15 a.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every da

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference, on Thursday, January 12, 2023, at 11:15 a.m. PT. A live webcast of the presentation will be accessible on the company's website, ir.travere.com, under the "Events & Presentations" section, and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all ba

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022 London Healthcare ConferenceWednesday, November 16, 2022, at 4:25 p.m. GMT (11:25 a.m. ET) 5th Annual Evercore ISI HealthCONx ConferenceTuesday, November 29, 2022, at 1:25 p.m. ET Piper Sandler Healthcare ConferenceThursday, December 1, 2022, at 10:30 a.m. ET BofA Securities 2022 Biotech SMID Cap ConferenceWednesday, December 7, 2022, at 12:15 p.m. ET Live webcasts of the presentations will be accessible on the company's website, ir.travere.com, under the "Events and Presentations" section.

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET. A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 4:00 p.m. PT. A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for trea

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. ET. A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. ET. A live webcast will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the nee

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that management will present a Company overview at the following upcoming virtual investor conferences in November: Jefferies 2021 London Healthcare ConferenceDate: Thursday, November 18, 2021Time: On-demand webcast available beginning 8:00 a.m. GMT (3:00 a.m. ET) 4th Annual Evercore ISI HealthCONx ConferenceDate: Tuesday, November 30, 2021Time: 10:30 a.m. ET Live webcasts will be available at https://ir.travere.com/events-presentations and archived replays will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bioph

Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan (p<0.0001) Sparsentan has been generally well-tolerated and consistent with the previously observed safety profile to date Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN). The PROTECT Study met its pre-specified interim primary efficacy endpoint w

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in June: Jefferies Virtual Healthcare Conference Date: Wednesday, June 2, 2021Time: 1:00 p.m. ET JMP Securities Life Sciences Conference Date: Wednesday, June 16, 2021Time: 11:00 a.m. ET BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology Date: Tuesday, June 22, 2021Time: 11:15 a.m. ET Live webcasts will be available at https://ir.travere.com/events-presentations and archived replays will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics we are in ra

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS). Following achievement of the interim proteinuria endpoint in the ongoing Phase 3 DUPLEX Study of sparsentan in FSGS, the Company conducted pre-New Drug Application (NDA) interactions with the U.S. Food and Drug Administration in pursuit of an accelerated approval submission in the U.S., and Marketing Authorization Application (MAA) pre-submission interactions with the European Medicines Agency (EMA) for conditional marketing authorization and accelerated assessment consideration in Europe. In recent

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 5:00 p.m. ET. A live webcast of the presentation will be available at https://ir.travere.com/events-presentations and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know th

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March: SVB Leerink 10th Annual Global Healthcare ConferenceDate: Wednesday, February 24, 2021Time: 1:00 p.m. ET Barclays Global Healthcare ConferenceDate: Wednesday, March 10, 2021Time: 11:30 a.m. ET Live webcasts will be available at https://ir.travere.com/events-presentations and archived replays will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment. Sparsentan, an investigational product candidate, demonstrated a statistically significant response on FPRE compared to the active control, irbesartan (p=0.0094). Preliminary results from the interim analysis suggest that to date in the study, sparsentan has been generally well-tolerated and has shown a comparable safet

Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company’s ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment. Sparsentan, an investigational